Abstract:Background Trimethylamine N-oxide (TMAO) is a metabolite produced by gut microbiota, and its potential impact on lipid metabolism in mammals has garnered widespread attention in the scientific community. Bovine fatty liver disease, a metabolic disorder that severely affects the health and productivity of dairy cows, poses a significant economic burden on the global dairy industry. However, the specific role and pathogenesis of TMAO in bovine fatty liver disease remain unclear, limiting our understanding and treatment of the condition. This study aims to construct a bovine fatty liver cell model and utilize an integrated approach combining transcriptomic, proteomic, and metabolomic data to investigate the molecular-level impact of TMAO on lipid metabolism and its potential regulatory mechanisms. Results We established an in vitro bovine fatty liver cell model and conducted a comprehensive analysis of cells treated with TMAO using high-throughput omics sequencing technologies. Bioinformatics methods were employed to delve into the regulatory effects on lipid metabolism, and several key genes were validated through RT-qPCR. Treatment with TMAO significantly affected 4,912 genes, 397 proteins, and 137 metabolites. KEGG enrichment analysis revealed that the significantly altered molecules were primarily involved in pathways related to the pathology of fatty liver disease, such as metabolic pathways, insulin resistance, hepatitis B, and the AMPK signaling pathway. Moreover, through joint analysis, we further uncovered that the interaction between TMAO-mediated AMPK signaling and oxidative phosphorylation pathways might be a key mechanism promoting lipid accumulation in the liver. Conclusions Our study provides new insights into the role of TMAO in the pathogenesis of bovine fatty liver disease and offers a scientific basis for developing more effective treatment strategies.

Trimethylamine N-oxide Induces Non-alcoholic Fatty Liver Disease by Activating the PERK Signaling Pathway

Gut microbiota metabolite trimethylamine N-oxide promoted NAFLD progression by exacerbating intestinal barrier disruption and intrahepatic cellular imbalance

Changes of flavin-containing monooxygenases and trimethylamine-N-oxide may be involved in the promotion of non-alcoholic fatty liver disease by intestinal microbiota metabolite trimethylamine

Trimethylamine N-Oxide Aggravates Liver Steatosis Through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease.

Trimethylamine-N-Oxide Pathway: A Potential Target for the Treatment of MAFLD

Trimethylamine-N-oxide (TMAO) mediates the crosstalk between the gut microbiota and hepatic vascular niche to alleviate liver fibrosis in nonalcoholic steatohepatitis

Gut microbiota metabolite TMAO promoted lipid deposition and fibrosis process via KRT17 in fatty liver cells in vitro

Nonalcoholic Fatty Liver Disease Development In Zebrafish Upon Exposure To Bis(2-Ethylhexyl)-2,3,4,5-Tetrabromophthalate, A Novel Brominated Flame Retardant

Trimethylamine N-oxide attenuates high-fat high-cholesterol diet-induced steatohepatitis by reducing hepatic cholesterol overload in rats

Trimethylamine N-Oxide Binds and Activates PERK to Promote Metabolic Dysfunction

Trimethylamine N-oxide promotes PERK-mediated endothelial-mesenchymal transition and apoptosis thereby aggravates atherosclerosis

Trimethylamine-N-oxide, a New Risk Factor for Non-alcoholic Fatty Liver Disease Changes the Expression of miRNA-34a, and miRNA-122 in the Fatty Liver Cell Model

Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target

Fish Oil Affects the Metabolic Process of Trimethylamine N-oxide Precursor Through Trimethylamine Production and Flavin-Containing Monooxygenase Activity in Male C57BL/6 Mice

Multi-omics Reveals the Mechanism of Trimethylamine N-oxide Derived from Gut Microbiota Inducing Liver Fatty of Dairy Cows

PERK specific inhibitor AMG-44 protects against Trimethylamine N-oxide (TMAO)-induced Endoplasmic Reticular Stress and Endothelial Dysfunction

Trimethylamine N-oxide Promotes Atherosclerosis Via CD36-dependent MAPK/JNK Pathway

Trimethylamine N‐Oxide Promotes Vascular Inflammation Through Signaling of Mitogen‐Activated Protein Kinase and Nuclear Factor‐κB

Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress/mitochondrial ROS/glycolysis pathways

Trimethylamine N-oxide (TMAO), choline and its metabolites are associated with the risk of nonalcoholic fatty liver disease

Trimethylamine-N-Oxide Aggravates Kidney Injury via Activation of p38/MAPK Signaling and Upregulation of HuR